SEC Filing Summary: SAB Biotherapeutics, Inc. (SABS)
Business Context and Reporting Period
This Form 8-K Current Report, dated March 17, 2026, announces that SAB Biotherapeutics, Inc. entered into a material definitive underwriting agreement for a public equity offering. The company is an emerging growth company incorporated in Delaware, with principal executive offices in Miami Beach, Florida.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 19,324,677 shares of Common Stock ("Firm Shares") at $3.85 per share and pre-funded warrants to purchase up to 2,753,246 shares at $3.8499 per warrant.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 3,311,688 additional shares ("Optional Shares").
- Estimated Net Proceeds: Approximately $69.7 million from the base offering, or $81.7 million if the over-allotment option is fully exercised.
- Underwriters: Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc., and Barclays Capital Inc.
- Closing Date: Expected on March 19, 2026, subject to customary conditions.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on the terms of the capital raise.
Material Changes and Outlook
The primary material change is the execution of the underwriting agreement to raise capital. The filing does not contain specific management commentary on operational outlook, risks, or contingencies beyond standard representations and warranties in the underwriting agreement. The proceeds are intended to fund the company's operations, though specific allocation details are not provided in this summary text.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after the March 19, 2026 closing.
- Confirm whether the underwriters exercised the 30-day option to purchase the 3,311,688 Optional Shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, indemnification obligations, and lock-up periods.
- Examine the Form S-3 shelf registration statement (File No. 333-292482) for the intended use of proceeds.
- Check subsequent filings for any updates on the exercise of the Pre-Funded Warrants.